ERBB2 and endometrial carcinoma: The two patients who had a PR in the ERBB2 mutation subgroup received a combination of paclitaxel, trastuzumab and everolimus for an adenocarcinoma of cervix and an endometrial carcinoma, both harboring ERBB2 S310Y mutation.